GeneFluidics Awarded $142,000 Subcontract for the Early Detection of Ovarian Cancer


MONTEREY PARK, CA – (PRWeb) – March 18, 2004 – The University of California, Los Angeles (UCLA) has awarded GeneFluidics a two-year, $142,000 subcontract to investigate the applicability of the Company’s molecular analysis platform for the early detection of ovarian cancer. Said research is part of a larger grant to the University from the Early Detection Research Network of the National Cancer Institute to identify and validate a low-sample volume, user-friendly, multi-assay molecular analysis platform for early-stage cancer discovery.

Ovarian cancer affects over 25,000 women in the United States every year, killing 16,000. This high mortality rate is partially due to the disease’s typically late diagnosis. While various molecular techniques have been investigated for ovarian cancer’s early detection, no technique has yet clinically demonstrated the avoidance of large sample volumes and exhaustive sample preparation. GeneFluidics’ platformrequires only microliter volumes of raw samples, while the Company’s microfluidic cartridges completely automate sample preparation for “plug and play” use.

“GeneFluidics’ technologies show great promise in early-stage cancer detection,” stated Dr. David Chia of UCLA’s Immunogenetics Center. “Demonstrating the clinical significance of a cancer screen requires the analysis of thousands of samples, both from early stage cancer and non-cancer patients. Collecting and analyzing these samples is very expensive and labor intensive — the GeneFluidics platform could provide a practical solution.”

Dr. Vincent Gau, GeneFluidics’ CEO and CTO agrees. “Dr. Chia surveyed the available technologies for the clinical validation of ovarian cancer screening, but saw GeneFluidics’ platform as that holding the most promise. We look forward to demonstrating our platform’s capability in ovarian cancer screening.”

About GeneFluidics:
GeneFluidics is commercializing a novel molecular analysis platform that integrates bionanotechnology and microfluidics. The platform has two distinct yet synergistic components – electrochemical detection, embodied in a multichannel reader and plastic sensor chips, and automated sample preparation, embodied in microfluidic cartridges and associated reader fluidic controls. By integrating these components, the platform enables the rapid detection and quantification of
genetic material, proteins, and small molecules in raw samples without the use of target amplification methods such as PCR.

CONTACT:
Vincent Gau – CEO

GeneFluidics
845 Meridian Street
Irwindale, CA 91010
626-263-3060

NOTE: Contact information on this page was updated from the original press release, which used the previous address for GeneFluidics.